SOURCE: Research and Markets

Research and Markets

February 16, 2016 11:03 ET

Global NASH Drugs Market Report -- Analysis, Technologies & Forecast 2015-2025 -- Key Vendors: American Diabetes Association, Arresto Biosciences & BHV Pharma

DUBLIN, IRELAND--(Marketwired - February 16, 2016) - Research and Markets has announced the addition of the "NASH Drugs Market, 2015-2025" report to their offering.

The NASH Drugs Market, 2015-2025' report provides a comprehensive study on the current landscape and the future outlook of the evolving pipeline of molecules in this area. With an expanding NAFLD and NASH population worldwide, there is a growing need for development of therapeutics in this disease area.

NASH is gradually emerging as the leading cause of liver transplants. While the field has garnered interest of several companies, there are no approved therapies till date. It is important to stress that the development pipeline of NASH has several promising candidates that are likely to result in many commercial success stories in the foreseen future.

Amongst other elements, the report elaborates on the new diagnostic solutions being developed and the upcoming opportunities for different stakeholders. As pharmaceutical companies continue to initiate and expand their research programs in this area, one of the key objectives outlined for this report is to understand the future potential of the market.

This is done by analyzing:

  • The epidemiology, patient population and staging of NASH in different geographies.
  • The NASH pipeline in terms of phase of development, type of molecule, route of administration and mechanism of action.
  • The likely evolution in the rate of diagnosis, drug treated patient population and the likely price of the drugs.
  • The associated constraints, in terms of undefined pathogenesis and the unavailability of non-invasive diagnostic tests, and the initiatives being carried out by the companies to overcome these.

The study provides a detailed scenario analysis to estimate the market forecast for the period till 2025. The research, analysis and insights presented in this report include potential sales of the drugs in late stages of development and expected to launch by 2025. Our opinions and insights, presented in this study, were influenced by the discussions that we conducted with experts in this area. These included senior representatives at BiOrion Technologies, Phenex Pharmaceuticals, Tobira Therapeutics, Verlyx Pharmaceuticals and Connexios.

Companies Mentioned Include:

  • Alnylam Pharmaceuticals
  • American Diabetes Association
  • Arresto Biosciences
  • AstraZeneca
  • BiOrion Technologies
  • BHV Pharma
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Johns Hopkins University
  • Kadmon
  • Kissei Pharmaceuticals
  • KrisaniBio
  • Kyorin Pharmaceutical
  • Raptor Pharmaceuticals
  • Regulus Therapeutics
  • Sanofi-Aventis
  • University of California
  • University of Perugia
  • Verlyx Pharma
  • Verva Pharmaceuticals
  • Viking Therapeutics
  • ViroBay
  • XTuit Pharmaceuticals
  • Zafgen
  • Zydus Cadila

Report Structure:

1. Preface

2. Executive Summary

3. Introduction

4. Treatment Options And Diagnostic Solutions

5. Market Dynamics

6. Market Overview

7. Upcoming Nash Drugs: Detailed Profiles

8. Market Sizing And Opportunity Analysis

9. Company Profiles

10. Conclusion

11. Interview Transcripts

12. Appendix1: Tabulated Data

13. Appendix 2: List Of Companies And Organizations

For more information visit

Sector: Pharmaceuticals

Image Available:

Contact Information

  • Research and Markets
    Laura Wood
    Senior Manager
    Fax from USA: 646-607-1907
    Fax from rest of the world: +353-1-481-1716